DFO
DFTX

Duquesne Family Office’s Definium Therapeutics DFTX Stock Holding History

Duquesne Family Office’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.8M Buy
+356,600
New +$8.81M 0.32% 62

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Duquesne Family Office's DFTX Position: Q2 2026 in Review

Duquesne Family Office opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 356,600 shares worth $16.8M. The stake represents 0.32% of the portfolio and ranks #62 among its holdings.

361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Duquesne Family Office held 356,600 shares of Definium Therapeutics worth $16.8M as of Q2 2026.
  • Definium Therapeutics was a new Duquesne Family Office position in Q2 2026.
  • Definium Therapeutics made up 0.32% of Duquesne Family Office's portfolio in Q2 2026, its #62 holding.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Duquesne Family Office's 13F filing for Q2 2026, filed 14 Aug 2026.